PITTSBURGH–(BUSINESS WIRE)–April 20, 2006–News From DSFV: DuPont’s (NYSE:DD) continued use of the chemical perfluorooctanoic acid (PFOA) keeps the company at financial risk, concludes a report ...
Phase I Trial of Recombinant Immunotoxin RFB4(dsFv)-PE38 (BL22) in Patients With B-Cell Malignancies
Randomized Trial of Radiotherapy Versus Concurrent Chemoradiotherapy Followed by Adjuvant Chemotherapy in Patients With American Joint Committee on Cancer/International Union Against Cancer Stage III ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results